ARVN vs. SNDX, MORF, RYTM, AKRO, DYN, CERE, LEGN, ITCI, VKTX, and JAZZ
Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Syndax Pharmaceuticals (SNDX), Morphic (MORF), Rhythm Pharmaceuticals (RYTM), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Cerevel Therapeutics (CERE), Legend Biotech (LEGN), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Syndax Pharmaceuticals has higher revenue and earnings than Arvinas. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
95.2% of Arvinas shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Syndax Pharmaceuticals currently has a consensus target price of $34.42, suggesting a potential upside of 76.50%. Arvinas has a consensus target price of $61.13, suggesting a potential upside of 129.05%. Given Syndax Pharmaceuticals' higher probable upside, analysts plainly believe Arvinas is more favorable than Syndax Pharmaceuticals.
Syndax Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -185.09%. Arvinas' return on equity of -53.32% beat Syndax Pharmaceuticals' return on equity.
In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Arvinas. MarketBeat recorded 9 mentions for Syndax Pharmaceuticals and 7 mentions for Arvinas. Syndax Pharmaceuticals' average media sentiment score of 1.36 beat Arvinas' score of 0.74 indicating that Arvinas is being referred to more favorably in the news media.
Syndax Pharmaceuticals received 197 more outperform votes than Arvinas when rated by MarketBeat users. However, 65.40% of users gave Arvinas an outperform vote while only 64.85% of users gave Syndax Pharmaceuticals an outperform vote.
Syndax Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.
Summary
Arvinas beats Syndax Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Arvinas News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
